ASX-listed Neurotech International has announced the expansion of its exclusive licence with Dolce Cann Global to include all neurological disorders, specifically autism, epilepsy, ADHD, alzheimer’s disease, huntington’s disease, multiple sclerosis, transverse myelitis, inflammatory brain disease, fibromyalgia, chronic fatigue and migraine.
Neurotech said latest clinical research shows inflammation, and more specifically neuroinflammation, is a well-recognised common feature in all neurological disorders.
Join the Cannabiz revolution
Want to stay ahead of the cannabis curve with the latest local and international news, analysis and intelligence and access to Australia's legal cannabis industry?
This article is included with our Premium subscription.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
